-
Mashup Score: 3World Lung 2024 – backing for ifinatamab’s pivotal move - 9 month(s) ago
The mid-stage Ideate-Lung01 study bears out ifinatamab-dxd’s efficacy in small-cell lung cancer.
Source: www.oncologypipeline.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2A failed trial is a failed trial, says China’s regulator - 10 month(s) ago
The NMPA has refused to back PFS, plus subgroup OS analyses, in fruquintinib’s stomach cancer study.
Source: www.oncologypipeline.comCategories: General Medicine News, Rare DiseaseTweet-
RT @JacobPlieth: NMPA to $HCM: no means no. Via @ApexOnco -> https://t.co/VLIGG4iUSU
-
-
Mashup Score: 6The month ahead: September’s upcoming events - 10 month(s) ago
It’s back to school for biotech, with a packed conference schedule.
Source: www.oncologypipeline.comCategories: General Medicine News, Hem/OncsTweet-
RT @ApexOnco: The month ahead: September’s upcoming oncology events https://t.co/iE1bamUv8q
-
-
Mashup Score: 6Merck shuffles the Kelun deck again - 10 month(s) ago
Claudin18.2 is out, but the US big pharma opts in to a new project.
Source: www.oncologypipeline.comCategories: General Medicine News, Hem/OncsTweet-
RT @JacobPlieth: $MRK shuffles the Kelun deck yet again. 1 + 1 + 7 - 2 + 1 - 1 = 7, right? Via @ApexOnco -> https://t.co/5SbB9QiMfc https:/…
-
-
Mashup Score: 10ESMO 2024 preview – conjugates in the spotlight - 11 month(s) ago
Early attention falls on ADCs originated by ProfoundBio, SystImmune, MediLink and Seagen.
Source: www.oncologypipeline.comCategories: General Medicine News, Hem/OncsTweet-
RT @JacobPlieth: It's (almost) time for #ESMO24 ! Check out my first preview, on ADCs. Via @ApexOnco -> https://t.co/qwJ8wSMoFW
-
-
Mashup Score: 6Novartis drops out of KRAS - 11 month(s) ago
While Roche, Lilly and Merck push on aggressively, Novartis throws in the towel.
Source: www.oncologypipeline.comCategories: General Medicine News, Hem/OncsTweet-
RT @JacobPlieth: $NVS just crashed out of KRAS. Via @ApexOnco -> https://t.co/wLrZndzVza $RHHBY $AMGN $BMY $MRK $LLY https://t.co/odMMz0bsRA
-
-
Mashup Score: 11Where next for TIGIT? - 12 month(s) ago
The implosion of Skyscraper-06 has a direct impact on at least two other TIGIT players.
Source: www.oncologypipeline.comCategories: General Medicine News, Hem/OncsTweet-
Why pharma just can’t seem to give up on the promise of targeting TIGIT, despite some recent late phase busts & only modest successes. 25 pivotal trials planning to recruit over 15,000 patients are ongoing! Excellent work as always from @JacobPlieth https://t.co/aL5yZDRV6X
-
-
Mashup Score: 3Bicara chases Merus - 12 month(s) ago
But ficerafusp is limited to HPV-negative disease, and petosemtamab’s safety looks better.
Source: www.oncologypipeline.comCategories: General Medicine News, Hem/OncsTweet-
RT @JacobPlieth: Bicara challenges $MRUS, but petosemtamab looks pretty safe for now. Via @ApexOnco -> https://t.co/Sk9bRzAlKl https://t.co…
-
-
Mashup Score: 4Takeda draws a cautious line under Iclusig - 1 year(s) ago
$100m buys an option over another third-gen drug, but Scemblix casts a long shadow.
Source: www.oncologypipeline.comCategories: General Medicine News, Hem/OncsTweet-
RT @ApexOnco: $TAK draws a cautious line under Iclusig https://t.co/R3Mjgv5v5H $NVS $BMY $PFE https://t.co/rpvfRGZ0Go
-
-
Mashup Score: 4Affimed tries to convince with seven patients - 1 year(s) ago
Luminice-203 yields its first topline data, but where are all the patients?
Source: www.oncologypipeline.comCategories: General Medicine News, Hem/OncsTweet-
RT @JacobPlieth: $AFMD toplines the first data from Luminice-203... in 7 patients. Via @ApexOnco -> https://t.co/8ujLQdPvdZ https://t.co/tw…
-
RT @JacobPlieth: Backing for $DSNKY $MRK pivotal move with ifinatamab-dxd, via @ApexOnco -> https://t.co/YqUYmyA4nw